TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.
Hirofumi TenshinJumpei TeramachiMohannad AshtarMasahiro HiasaYusuke InoueAsuka OdaKotaro TanimotoSo ShimizuYoshiki HigaTakeshi HaradaMasahiro OuraKimiko SogabeTomoyo HaraRyohei SumitaniTomoko MaruhashiMayu SebeRie TsutsumiHiroshi SakaueItsuro EndoToshio MatsumotoEiji TanakaMasahiro AbePublished in: Clinical & translational immunology (2022)
TAK1 inhibition with LLZ may become a novel treatment strategy to effectively alleviate inflammasome-mediated inflammation and RANKL-induced osteoclastic bone destruction in joints alongside its potent suppression of TNF-α and IL-6 production and proteinase-mediated pathological processes in RA.
Keyphrases
- rheumatoid arthritis
- nlrp inflammasome
- bone loss
- oxidative stress
- disease activity
- bone mineral density
- mouse model
- ankylosing spondylitis
- interstitial lung disease
- poor prognosis
- diabetic rats
- soft tissue
- nuclear factor
- high glucose
- signaling pathway
- postmenopausal women
- bone regeneration
- systemic lupus erythematosus
- transforming growth factor
- immune response
- drug induced
- endothelial cells
- inflammatory response
- idiopathic pulmonary fibrosis
- body composition